Allena Pharmaceuticals Announces Agreement With Pontifax Medison Finance

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) on September 30, 2020 announced a $25 million convertible debt financing agreement with Pontifax Medison Finance, the healthcare-dedicated venture and debt fund of the Pontifax life science funds.

According to the terms of the agreement with Pontifax, Allena will have right to use up to $25 million in convertible debt financing in three tranches, which will mature over a four year period and have an interest-only period for the first two years. Upon the closing of this transaction, the company has accessed the first tranche of $10 million, and has the option to draw the second tranche of $5 million at any time over the next 12 months and the third tranche of $10 million by December 29, 2021, subject to certain conditions.

H.C. Wainwright announced it was Initiated coverage of Allena Pharmaceuticals Inc. in a research note on June 01, 2020. Credit Suisse rated the stock as an Outperform in a research noted published on July 10, 2019. Robert W. Baird rated the stock as an Outperform in a research note published on January 18, 2019.

ALNA Recent Trade

The share price of ALNA ascended by $0.27 during the exchanging session on 09/30/20 to exchange at $1.48. Allena Pharmaceuticals Inc. stock has an exchanging volume of 31.42 million shares, which is high, contrasted with its 3-months average volume of 1.33M shares. Its market capitalization has now reached to $54.63M.

ALNA Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, ALNA price has rose by 22.31%. In the course of past three months sees the stock go down around -6.92%, while it has gain 85.00% over the past six months and -45.79% since the start of the year.

ALNA Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), Allena Pharmaceuticals Inc. posted -$0.26 earnings per share (EPS) which was above the consensus estimate of -$0.3 by $0.04, which represents to an expansion by 13.30%.

ALNA Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Allena Pharmaceuticals Inc. has seen its stock exchanging -36.75% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +38.32% above its three-month low. A more extensive look sees ALNA exchanging -76.51% beneath its 52-week high and 181.90% above from its 52-week low price.

ALNA Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 12.09%, while it has a month to month instability of 10.98%. The company has an ATR (Average True Range) of 0.15.

Leave a Comment